Pubmed Biomarker Relation Statistics Odds
(95% CI)		 P-value Description
34306255 GABPA type II EC p<0.01 The expression of GABPA was markedly correlated with type II EC
29169184 HER2 histologic type p<0.001 A gradual increase in number of HER2 high tumours was observed according to aggressiveness of histologic type and grade
35156640 p53 p= 0.001 Elevated Ki67 index and p53 overexpression was associated with type II morphology
35156640 Ki-67 p= 0.001 Elevated Ki67 index and p53 overexpression was associated with type II morphology
29169184 HER2 non-endometrioid tumours p=0.03 High HER2 (SI 9) was associated with poor outcome within non-endometrioid tumours
29114696 cancer antigen 15-3 levels non-endometrioid tumours p<0.05 Serum cancer antigen 15-3 levels were significantly higher in patients with Type 2 histology,
29096882 Asparaginase-like protein 1 type I (HR: 2.64, CI: 1.47–4.74 p=0.001 ASRGL1 was also found to have independent prognostic value within the endometrioid endometrial carcinoma patients after adjusting for age and histologic grade
29096882 Asparaginase-like protein 1 type I p<0.001 The proportion of lesions with low ASRGL1 expression increased significantly with higher grade within the endometrioid endometrial carcinoma subgroup
29096882 Asparaginase-like protein 1 type I p=0.012 Of the non-endometrioid tumors 56% had low expression of ASRGL1, which was significantly higher than for the endometrioid grade 3 tumor
28618925 DJ-1 grade/histologic type p≤0.05 The difference of DJ-1 serum levels remains statistically significant when we compared EEC-G3 and SEC/CCEC versus EEC-G2
28618925 CA125 histologic type p≤0.05 The difference in CA125 levels remains statistically significant for each EC subtype (EEC-G1 = 36 UI/L, EEC-G2 = 24 UI/L, EEC-G3 = 35 UI/L, and SEC/CCEC = 34 UI/L) compared to controls
28618925 HE4 histologic type p≤0.05 HE4 levels were significantly different in when each EC subtype (EEC-G1 = 77 pmol/mL, EEC-G2 = 73 pmol/mL, EEC-G3=92pmol/mL, and SEC/CCEC=79 pmol/mL) was compared to controls
28187032 Tyrosine Phosphatase SHP-1 Ec p=0.0005 A significantly higher SHP-1 expression was observed in the Ec group compared with the serous (Sc) group
34076790 miRNA 27a type I 28 VS 8 U=54.0* p=0.027 A signifcant association between miRNA 27a and tumour type was found; as it was overexpressed in endometrial cancer type I than type II
28155970 p53 USC sensitive (74%)and specific ( 92%) p<0.001 Diffuse p53 staining emerged as the most sensitive (74%, and specific ( 92%) markers for the differentiation of USC from grade 3 EAC
28155970 p16 histologic type/grade p=0.003 p16 staining patterns can differentiate between high-grade EAC and USC. A discrimination score was obtained for p16 which was found to be statistically significant
28155970 p16 USC sensitive (74% ) and specific (88% ) p<0.001 Diffuse p16 staining emerged as the most sensitive (74% ) and specific (88% ) markers for the differentiation of USC from grade 3 EAC
28155970 Ret finger protein histologic type/grade p<0.001 The RFP scores in each histologic type were compared: the mean RFP score was 1.54 in grade 1 EAC, 4.31 in grade 3 EAC and 6.31 in USC
27648714 L1CAM non-endometrioid histology OR, 9.9 L1CAM positivity was associated with non-endometrioid histology
27549092 CA-125 pure ECCC p=0.02 The number of metastatic lymph nodes occurred more frequently in patients with pure ECCC than with mixedtype histology
27549092 CA-125 pure ECCC p=0.04 The presence of advanced-stage disease occurred more frequently in patients with pure ECCC than with mixedtype histology
27153547 ERRα serous histological type p <0.01 ERRα was expressed in all examined tissues and the elevated expression levels of ERRα were associated with serous histological type
26743472 L1CAM type I p<0.001 L1CAM expression was also strongly associated with in the endometrioid type in TCGA series
26743472 L1CAM type II p=0.049 L1CAM expression was also strongly associated with non-endometrioid subtypes in TCGA series
32630554 MSX1 type I p<0.001 A significant stronger expression of MSX1 was found in endometrioid endometrial carcinomas
26708131 Co-expression GAL-3 and CRIP-1 histological type There was a significant correlation between high co-expression of the two proteins and the histological type
26607777 YKL-40 non-endometrioid histology p=0.022 YKL-40 levels were significantly higher in non-endometrioid histology compared with endometrioid adenocarcinoma
26308378 ATAD2 non-endometrioid subtypes p<0.001 Comparing ATAD2 expression with clinical and histopathological variables for aggressive endometrial cancer, we find a highly significant association between high ATAD2 expression and non-endometrioid subtypes
25544793 ZEB1 subtype p=0.031 The ZEB1 expression in endometrial biopsy significantly associated with subtype
25282036 p53 between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 P53 showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
25282036 IMP2 between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 IMP2 showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
25282036 IMP3 between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 IMP3 showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
25282036 cyclin E1 between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 Cyclin E1 showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
25282036 HMGA2 between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 HMGA2 showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
25282036 FolR1 between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 FolR1 showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
30374843 Autotaxin endometrioid histotype p=0.038 ATX were observed in patients with endometrioid histotype compared with special histotypes
25282036 p16 between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 P16 showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
25282036 nuclear PTEN between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 Nuclear PTEN showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
25282036 estrogen receptor between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC) p<.005 Estrogen receptor showed significant differences with thresholds in IHC value scale between endometrioid type (EEC) grades 1, 2, and 3 and serous type (SC)
24849812 FOXA1 non-endometrioid histology p = 0.002 LowFOXA1 expression (score index from 0–4) was significantly correlated with non-endometrioid histology
24762589 PTEN endometrioid histotype p=0.013 There was no clear association between PTEN positivity and clinicopathological parameters except more relevance with endometrioid histotype
24530564 miR-203 type I p<0.001 Hypermethylation of miR-203 was detected in 52% of type I endometrioid endometrial carcinomas (n=131) but was not seen in any of 10 uninvolved normal endometria
24460345 SPAG9 stage I EC [median 16.3, range 12.7-44.7)] VS [median 14.1 (range, 4.3-65.3)] p<0.001 SPAG9 levels were also significantly higher in FIGO stage I EC cases [median 16.3, range 12.7-44.7)] when compared to controls [median 14.1 (range, 4.3-65.3)]
24335662 estrogen receptor-α CCS/USC 54.5% and 0.0% p=0.04 The cancer-specific 5-year survival rates of patients with USC without an expression of ER-α and USC with an expression of ER-α were 54.5% and 0.0%, respectively
24222154 E-Cadherin endometrioid carcinomas p=0.05 E-Cadherin overexpression was associated with the subgroup of endometrioid carcinomas
24211402 Serum HE4 RFS/endometrioid subtype HR=2.86, 95% CI 1.25-6.51 p=0.012 Cox multivariate analysis demonstrated that elevated HE4 was an independent predictor of recurrence-free survival in the endometrioid subtype
30314462 API adenocarcinoma 6.28; 95% c [CI]: 5.43–6.95 The median API value was decreased after treatment in patients with adenocarcinoma
24145649 napsin A clear cell histotype 0.98 (95% CI, 0.86-1) Positive predictive value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88
23896713 Ki-67 CSS/PFS High proliferative index of Ki-67 were significant prognostic factors for both progression-free survival and CSS in a univariate analysis
23782748 combined OATP1B3/CTR1 type I p=0.0005 The high expression levels of OATP1B3 were significantly correlated with type I tumor
23114646 EMT histological type p<0.01 EMT status, which was represented by both reduced E-cadherin and nuclear expression of Snail, was significantly associated with histological type,
22644303 pHH3 type II p<0.0001 Patients with type II carcinomas expressed significantly more pHH3 than endometrioid tumours
22644303 survivin type II p<0.0001 Patients with type II carcinomas expressed significantly more survivin than endometrioid tumours
22644303 pHH3 histological type p<0.0001 The rate of pHH3-positive cells was significantly associated with histological type
22617129 bFGF high-grade endometrioid and clear cell histology p<0.001 Tumour bFGF was significantly associated with high-grade endometrioid and clear cell histology
22250726 HMGA2 histologic type/serous carcinomas p<0.0001 There was a statistically significant difference between HMGA2 staining in serous and endometrioid carcinomas with regard to both extent and composite score, with higher expression in serous carcinomas
22250726 HMGA2 histologic type p<0.0001 There was a statistically significant difference in HMGA2 staining in the TMAs between the serous and grade 3 endometrioid carcinomas, with higher expression in the former
30314462 API squamous carcinoma 7.44; 95% CI: 3.04–8.46 The median API value was decreased after treatment in patients with squamous carcinoma
22209294 phosphatidylinositol 3'-kinase pathway alteration high-grade endometrioid carcinomas p=.045 Mutations of both exons were more common in low-grade than in high-grade endometrioid carcinomas, and the correlation between exon 9 mutation and lower grade was statistically significant
22027748 p16 discrimination/ serous Overexpression of p16 was found in 78% of the serous papillary patients versus 36% of the endometrioid patients.
21764107 SUVmax histology p=0.025 There were significant correlations between the SUVmax of the primary tumor and histology
21616994 GDF-15 non endometrioid histology p≤0.001 High plasma GDF-15 was significantly associated with nonendometrioid histology,
21505452 Tetraspanin CD151 histologic type/grade p<0.001 Expression of CD151 was significantly higher in uterine papillary serous and clear cell carcinoma than in grade 3 endometrioid carcinoma, sarcoma or carcinosarcoma
21505452 Tetraspanin CD151 uterine papillary serous and clear cell carcinoma p<0.001 Expression of CD151 was significantly higher in uterine papillary serous and clear cell carcinoma than in grade 3 endometrioid carcinoma, sarcoma or carcinosarcoma
21468050 HE4 type I p=0.016 Immunoreactivity for HE4 was significantly stronger in endometrioid ECs compared with non-endometrioid ECs
21242118 Stathmin DFS/type II p =0.002 When analyzing the endometrioid group separately, Stathmin in curettage specimens yielded a significant correlation with disease-specific survival
21242118 Stathmin DFS/typeII p =0.06 When analyzing the endometrioid group separately, Stathmin in hysterectomy specimen yielded a significant correlation with disease-specific survival .
21228930 Nrf2 ESC p<0.001 Among the malignant cases, Nrf2 was positive in 28 (68%) of 50 ESCs, which was significantly more than in 3 (6%) of 50 endometrioid carcinomas ,2 (13%) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers.
29869299 ER-alpha, low-grade ESS. p=0.020 ER-alpha showed significantly higher and stronger expression in low-grade ESS.
20570475 NLR uterine sarcomas p<0.05 The NLR was more powerful for the preoperative diagnosis of uterine sarcomas than serum CA-125 levels (sensitivity, 74.5% vs. 52.3%; specificity, 70.3% vs. 50.5%; positive predictive value, 29.5% vs. 15.1%; negative predictive value, 94.3% vs. 86.5%; accuracy, 60.6% vs. 49.6%;
18565690 CD10 SSE CD10 was expressed in two-third of SSE
18458692 ADAM19 type II p=0.042 Those with non-adenocarcinoma had a higher expression level
18376386 beta-catenin endometrial stromal sarcomas Nuclear beta-catenin immunoreactivity was detected in 11 low-grade endometrial stromal sarcomas (92%) and 6 undifferentiated endometrial sarcomas (75%).
18313673 aquaporin-1 (AQP1) type II p<0.001 The AQP1/IMD ratio was significantly higher for endometrioid adenocarcinoma than for endometrial hyperplasia
18223334 The oncofetal protein IMP3 clear cell carcinoma p<0.0001 ESC showed a higher frequency of IMP3 protein expression (94%) than clear cell carcinoma (50%), and the difference was highly significant
18223334 The oncofetal protein IMP3 serous carcinomas p<0.001 Serous carcinomas including their putative precursor lesions showed a significant different staining pattern for IMP3 compared with type I endometrial cancers and their precursor lesions
17582475 FOLR1 serous histology 16/32 [50%] p<0.001 Overexpression of FOLR1 was observed in 50/292 (17%) cases and was seen more often in tumors with serous histology
17527071 MSI endometrioid type 20% vs. 0% p<0.001 The incidence of MSI-high phenotype was significantly higher in endometrioid type than in nonendometrioid serous type
17504383 p53 type II p=0.001 Positive staining of p53 was significantly correlated with a nonendometrioid histology
29869299 PR low-grade ESS. p=0.001 PR, and AR showed significantly higher and stronger expression in low-grade ESS.
17099695 HIF-1alpha type II p<0.001 High expression of HIF-1alpha, VEGF, Ki-67 and p53 were significantly more frequent in type II than type I endometrial adenocarcinoma
17099695 HIF-1alpha type I and type II 26% of type I revealed high expression compared to 86% of type II p<0.001 IHC analysis revealed a significant difference in high expression of HIF-1α between type I and type II endometrial adenocarcinoma
16710036 HER-2 histologic types p<.0001 For all histologic types, the rate of HER-2 expression and amplification was remarkably different
16322283 EIG121 type I endometrial carcinoma p<0.01 The level of EIG121 expression was significantly elevated in type I endometrial carcinoma overall, to >4.6-fold of its level in benign endometrium.
16021566 beta-catenin (CTNNB1) synchronous endometrioid carcinomas Nuclear immunoreactivities for beta -catenin and CTNNB1 mutations were restricted to independent uterine and ovarian tumors and were absent in all of the metastatic tumors, providing direct evidence for a divergence of molecular oncogenetic mechanisms in the subset of synchronous endometrioid carcinomas.
15938828 CD10 ESS CD10 was only weakly expressed in 1 case
15938828 SMA ESS Strong expression of SMA was obtained in all 10 cellular leiomyomas
15867230 Human kallikrein 6 (hK6) USPC p=0.005 Serum and plasma hK6 values in USPC patients (mean ± SE, 6.1 ± 1.1; range, 1.9-15.6) were significantly higher than those in endometrioid carcinoma patients
15678850 c-erbB2 The overexpression of c-erbB2 protein in the examed cases was correlated with the clinical status, histological type of the tumour and the differentiation degree
15328195 E-Cadherin papillary serous or clear cell histology Kendall tau: -0.14, . p=0.12 E-Cadherin expression was negatively correlated with papillary serous or clear cell histology
29869299 AR low-grade ESS. p=0.045 ER-alpha, PR, and AR showed significantly higher and stronger expression in low-grade ESS.
15032075 p53 histologic type p=.0029 p53 protein was expressed exclusively in invasive tumors and was related strongly to histologic type
12948417 PTEN histological classification p<0.0001 Loss of PTEN expression in patients with endometrial carcinoma was significantly related to histological classification
11903603 MUC1 histologic type p=0.006 Membranous MUC1 positivity was statistically more frequent in endometrioid carcinomas compared with carcinomas of non-endometrioid type
11520144 EMA subtypes p=0.012 In adenocarcinomas, EMA overexpression had a positive correlation with nonendometrioid subtypes
10202671 HER-2/neu subtype p=0.002 Amplification was associated with clear cell and serous subtypes
10202671 HER-2/neu clear cell type p=0.006 Overexpression HER-2/neu with only clear cell type
9829742 Ki-67 histological type p=0.03 The expression of Ki-67 was significantly associated with histological type
8695259 p53 uterine papillary serous cancers and clear cell cancer p<0.001 Strong p53 expression (> 75% of the cells stained) was more common in uterine papillary serous cancers and clear cell cancers than in other tumour subtypes
1361478 HER-2/neu stage I p=0.0007 In stage I patients (203), the 5-year progression-free survival was 62% for the strong and 97% for the nonstaining groups
1361478 HER-2/neu stage I p=0.0017 In stage I patients (203), the 5-year progression-free survival was 62% for the strong and 97% for the nonstaining groups, This retained independent significance when subjected to multivariate analysis

Institutes for Systems Genetics, West China Hospital
     Copyright @ 2023 ISG. All Rights Reserved.